4,393 Shares in The Clorox Company (NYSE:CLX) Purchased by Pallas Capital Advisors LLC

Pallas Capital Advisors LLC bought a new position in The Clorox Company (NYSE:CLX - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 4,393 shares of the company's stock, valued at approximately $647,000.

Several other large investors have also made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Clorox by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 15,507,152 shares of the company's stock worth $2,518,517,000 after buying an additional 124,428 shares during the period. Geode Capital Management LLC raised its position in shares of Clorox by 2.3% in the 4th quarter. Geode Capital Management LLC now owns 3,098,302 shares of the company's stock worth $501,925,000 after buying an additional 69,969 shares during the period. Stifel Financial Corp raised its position in shares of Clorox by 0.4% in the 4th quarter. Stifel Financial Corp now owns 2,344,408 shares of the company's stock worth $380,761,000 after buying an additional 9,582 shares during the period. Norges Bank purchased a new position in shares of Clorox in the 4th quarter worth $259,041,000. Finally, Northern Trust Corp raised its position in shares of Clorox by 18.2% in the 4th quarter. Northern Trust Corp now owns 1,494,265 shares of the company's stock worth $242,684,000 after buying an additional 230,173 shares during the period. 78.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. UBS Group cut their target price on Clorox from $176.00 to $154.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. Citigroup cut their price objective on Clorox from $165.00 to $150.00 and set a "neutral" rating on the stock in a research report on Monday, April 14th. Wells Fargo & Company cut their price objective on Clorox from $145.00 to $142.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Morgan Stanley cut their price objective on Clorox from $165.00 to $150.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Finally, Barclays cut their price objective on Clorox from $134.00 to $129.00 and set an "underweight" rating on the stock in a research report on Wednesday, May 7th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and one has given a buy rating to the stock. According to MarketBeat, Clorox presently has a consensus rating of "Hold" and a consensus target price of $151.23.

Insider Buying and Selling

In other news, Director Pierre R. Breber purchased 4,000 shares of the firm's stock in a transaction that occurred on Wednesday, May 7th. The stock was acquired at an average cost of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the purchase, the director now owns 4,000 shares of the company's stock, valued at approximately $546,280. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.57% of the company's stock.

Clorox Stock Down 3.3%

Shares of Clorox stock traded down $4.25 during trading hours on Friday, hitting $123.03. 1,709,082 shares of the company's stock traded hands, compared to its average volume of 1,358,800. The stock has a 50 day simple moving average of $134.91 and a 200-day simple moving average of $148.48. The company has a quick ratio of 0.60, a current ratio of 0.94 and a debt-to-equity ratio of 20.52. The company has a market cap of $15.16 billion, a PE ratio of 33.61, a PEG ratio of 2.62 and a beta of 0.54. The Clorox Company has a twelve month low of $122.84 and a twelve month high of $171.37.

Clorox (NYSE:CLX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $1.45 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.12). The business had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.74 billion. Clorox had a net margin of 6.38% and a return on equity of 316.87%. The firm's revenue was down 8.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.71 earnings per share. Equities research analysts anticipate that The Clorox Company will post 7.15 earnings per share for the current fiscal year.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.